

Special Issue

Neuro-Immune Orchestration in Brain Tumors: From Molecular Signatures to Therapeutic Innovation

Message from the Guest Editors

Recent advances in neuroimmunology and oncology have led to significant progress in understanding the biology of brain tumors, revealing complex interactions between neural tissue, immune cells, and malignant cells. This Special Issue, "Neuro-Immune Orchestration in Brain Tumors: From Molecular Signatures to Therapeutic Innovation", aims to provide a comprehensive picture of the complex relationship between the nervous and immune systems within the context of brain tumors. The unique immunological context of the central nervous system represents both challenges and opportunities in cancer therapy. Understanding these complexities, from the specialized blood–brain barrier to unique immune privilege mechanisms, is critical in developing effective therapies. This Special Issue will highlight cutting-edge developments in molecular profiling, innovative therapeutic approaches, and new paradigms in neuroimmune interactions. For this Special Issue, we welcome submissions of original research articles, reviews, and perspectives addressing:

- molecular and cellular aspects;
- technological innovations;
- clinical translation;
- other emerging concepts.

Guest Editors

Dr. Mitsugu Fujita
Dr. Masasuke Ohno
Dr. Shunichiro Kuramitsu

Deadline for manuscript submissions

closed (1 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223488

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)